Daiwa Initiates Coverage on Pharmaron with 'Buy' Rating, Sets HK$25.5 Price Target

Stock News07-08

Daiwa has initiated coverage on Pharmaron (HKEX: 03759) H-shares with a 'Buy' rating and a target price of HK$25.5.

The firm believes Pharmaron stands to benefit from a recovery in global biopharma funding and the ongoing outsourcing demand from multinational pharmaceutical and biotech clients.

The company's laboratory services business maintains a robust growth trajectory. Given the strong growth in new contract signings in the first quarter, Daiwa expects revenue growth for this segment to reach 13% to 15% from 2026 to 2028.

Concurrently, the Chemistry, Manufacturing, and Controls (CMC) business is progressing towards commercialization and is set to become a key growth driver in the short to medium term, with an anticipated compound annual growth rate of 24% from 2026 to 2028.

Daiwa noted that with new contract signings in the first quarter increasing by over 30% year-on-year and a solid first-quarter performance, the company is believed to be on track to achieve its guidance of 12% to 18% year-on-year revenue growth for 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1192222211?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-08 14:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1192222211","market":"nz","top_or_hot":-1,"title":"Daiwa Initiates Coverage on Pharmaron with 'Buy' Rating, Sets HK$25.5 Price Target","media":"Stock News","content":"<p>Daiwa has initiated coverage on <b>Pharmaron</b> (<b>HKEX: 03759</b>) H-shares with a 'Buy' rating and a target price of HK$25.5.<br><br>The firm believes Pharmaron stands to benefit from a recovery in global biopharma funding and the ongoing outsourcing demand from multinational pharmaceutical and biotech clients.<br><br>The company's laboratory services business maintains a robust growth trajectory. Given the strong growth in new contract signings in the first quarter, Daiwa expects revenue growth for this segment to reach 13% to 15% from 2026 to 2028.<br><br>Concurrently, the Chemistry, Manufacturing, and Controls (CMC) business is progressing towards commercialization and is set to become a key growth driver in the short to medium term, with an anticipated compound annual growth rate of 24% from 2026 to 2028.<br><br>Daiwa noted that with new contract signings in the first quarter increasing by over 30% year-on-year and a solid first-quarter performance, the company is believed to be on track to achieve its guidance of 12% to 18% year-on-year revenue growth for 2026.<br><br></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Daiwa Initiates Coverage on Pharmaron with 'Buy' Rating, Sets HK$25.5 Price Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDaiwa Initiates Coverage on Pharmaron with 'Buy' Rating, Sets HK$25.5 Price Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-08 14:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Daiwa has initiated coverage on <b>Pharmaron</b> (<b>HKEX: 03759</b>) H-shares with a 'Buy' rating and a target price of HK$25.5.<br><br>The firm believes Pharmaron stands to benefit from a recovery in global biopharma funding and the ongoing outsourcing demand from multinational pharmaceutical and biotech clients.<br><br>The company's laboratory services business maintains a robust growth trajectory. Given the strong growth in new contract signings in the first quarter, Daiwa expects revenue growth for this segment to reach 13% to 15% from 2026 to 2028.<br><br>Concurrently, the Chemistry, Manufacturing, and Controls (CMC) business is progressing towards commercialization and is set to become a key growth driver in the short to medium term, with an anticipated compound annual growth rate of 24% from 2026 to 2028.<br><br>Daiwa noted that with new contract signings in the first quarter increasing by over 30% year-on-year and a solid first-quarter performance, the company is believed to be on track to achieve its guidance of 12% to 18% year-on-year revenue growth for 2026.<br><br></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EWH","symbol_name":"香港ETF-iShares MSCI","start_time":0,"source_url":"","article_id":"1192222211","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1192222211","pubTimestamp":1783492913,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Daiwa has initiated coverage on Pharmaron (HKEX: 03759) H-shares with a 'Buy' rating and a target price of HK$25.5.The firm believes Pharmaron stands to benefit from a recovery in global biopharma...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300759":"康龙化成","EWH":"香港ETF-iShares MSCI","BK1576":"医药外包概念","BK1141":"生命科学工具和服务","03759":"康龙化成","BK0216":"研究试验"},"translate_title":"大和首次给予康龙化成“买入”评级，目标价为25.5港元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300759":1,"03759":1,"EWH":1},"content_text":"Daiwa has initiated coverage on Pharmaron (HKEX: 03759) H-shares with a 'Buy' rating and a target price of HK$25.5.The firm believes Pharmaron stands to benefit from a recovery in global biopharma funding and the ongoing outsourcing demand from multinational pharmaceutical and biotech clients.The company's laboratory services business maintains a robust growth trajectory. Given the strong growth in new contract signings in the first quarter, Daiwa expects revenue growth for this segment to reach 13% to 15% from 2026 to 2028.Concurrently, the Chemistry, Manufacturing, and Controls (CMC) business is progressing towards commercialization and is set to become a key growth driver in the short to medium term, with an anticipated compound annual growth rate of 24% from 2026 to 2028.Daiwa noted that with new contract signings in the first quarter increasing by over 30% year-on-year and a solid first-quarter performance, the company is believed to be on track to achieve its guidance of 12% to 18% year-on-year revenue growth for 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1192222211","isCrawlerRequest":true}